AR127054A1 - Composiciones y métodos para tratar sinucleinopatías - Google Patents
Composiciones y métodos para tratar sinucleinopatíasInfo
- Publication number
- AR127054A1 AR127054A1 ARP220102483A ARP220102483A AR127054A1 AR 127054 A1 AR127054 A1 AR 127054A1 AR P220102483 A ARP220102483 A AR P220102483A AR P220102483 A ARP220102483 A AR P220102483A AR 127054 A1 AR127054 A1 AR 127054A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- synuclein
- acid sequence
- amino acid
- synucleinopathy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21197120 | 2021-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127054A1 true AR127054A1 (es) | 2023-12-13 |
Family
ID=78049153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102483A AR127054A1 (es) | 2021-09-16 | 2022-09-13 | Composiciones y métodos para tratar sinucleinopatías |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US12077578B2 (https=) |
| EP (1) | EP4401770A2 (https=) |
| JP (1) | JP2024534947A (https=) |
| KR (1) | KR20240055758A (https=) |
| CN (1) | CN117915952A (https=) |
| AR (1) | AR127054A1 (https=) |
| AU (1) | AU2022348798A1 (https=) |
| CA (1) | CA3230055A1 (https=) |
| CL (2) | CL2024000753A1 (https=) |
| IL (1) | IL311344A (https=) |
| MX (1) | MX2024002970A (https=) |
| WO (1) | WO2023041524A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018014281A2 (pt) * | 2016-11-15 | 2018-12-18 | H Lundbeck As | agentes, usos e métodos para o tratamento da sinucleinopatia |
| EP4401770A2 (en) * | 2021-09-16 | 2024-07-24 | H. Lundbeck A/S | Compositions and methods for treating synucleinopathies |
| CN121794293A (zh) * | 2023-09-14 | 2026-04-03 | 豪夫迈·罗氏有限公司 | 抗体制剂 |
| WO2025186235A1 (en) | 2024-03-05 | 2025-09-12 | H. Lundbeck A/S | Compositions and methods for treating multiple system atrophy (msa) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2361928T3 (pl) * | 2003-05-19 | 2017-09-29 | Prothena Biosciences Limited | Skrócone fragmenty alfa-synukleiny w chorobie z ciałami Lewy'ego |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| WO2016077687A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| WO2017176835A2 (en) * | 2016-04-06 | 2017-10-12 | Imago Pharmaceuticals, Inc. | Therapeutic antibodies for treatment of neurodegeneration |
| BR112018014281A2 (pt) * | 2016-11-15 | 2018-12-18 | H Lundbeck As | agentes, usos e métodos para o tratamento da sinucleinopatia |
| JOP20190227A1 (ar) * | 2017-03-31 | 2019-09-30 | Biogen Int Neuroscience Gmbh | تركيبات وطرق لعلاج اعتلالات السينوكلين |
| EP4401770A2 (en) | 2021-09-16 | 2024-07-24 | H. Lundbeck A/S | Compositions and methods for treating synucleinopathies |
-
2022
- 2022-09-13 EP EP22789489.6A patent/EP4401770A2/en active Pending
- 2022-09-13 IL IL311344A patent/IL311344A/en unknown
- 2022-09-13 JP JP2024515041A patent/JP2024534947A/ja active Pending
- 2022-09-13 MX MX2024002970A patent/MX2024002970A/es unknown
- 2022-09-13 CN CN202280060631.5A patent/CN117915952A/zh active Pending
- 2022-09-13 AU AU2022348798A patent/AU2022348798A1/en active Pending
- 2022-09-13 CA CA3230055A patent/CA3230055A1/en active Pending
- 2022-09-13 KR KR1020247008828A patent/KR20240055758A/ko active Pending
- 2022-09-13 WO PCT/EP2022/075402 patent/WO2023041524A2/en not_active Ceased
- 2022-09-13 AR ARP220102483A patent/AR127054A1/es unknown
-
2023
- 2023-06-26 US US18/341,437 patent/US12077578B2/en active Active
-
2024
- 2024-03-13 CL CL2024000753A patent/CL2024000753A1/es unknown
- 2024-07-15 US US18/773,301 patent/US20250084156A1/en active Pending
- 2024-07-16 US US18/774,629 patent/US12351624B2/en active Active
- 2024-07-16 US US18/774,608 patent/US12358974B2/en active Active
- 2024-07-16 US US18/774,646 patent/US12358975B2/en active Active
- 2024-12-03 CL CL2024003713A patent/CL2024003713A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240025979A1 (en) | 2024-01-25 |
| WO2023041524A3 (en) | 2023-05-11 |
| WO2023041524A2 (en) | 2023-03-23 |
| CL2024003713A1 (es) | 2025-04-21 |
| IL311344A (en) | 2024-05-01 |
| JP2024534947A (ja) | 2024-09-26 |
| US20240400661A1 (en) | 2024-12-05 |
| US20240400660A1 (en) | 2024-12-05 |
| EP4401770A2 (en) | 2024-07-24 |
| CL2024000753A1 (es) | 2024-09-23 |
| US12358974B2 (en) | 2025-07-15 |
| US20250084156A1 (en) | 2025-03-13 |
| KR20240055758A (ko) | 2024-04-29 |
| US12351624B2 (en) | 2025-07-08 |
| CA3230055A1 (en) | 2023-03-23 |
| US12077578B2 (en) | 2024-09-03 |
| US20240400662A1 (en) | 2024-12-05 |
| US12358975B2 (en) | 2025-07-15 |
| CN117915952A (zh) | 2024-04-19 |
| AU2022348798A1 (en) | 2024-03-14 |
| MX2024002970A (es) | 2024-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR127054A1 (es) | Composiciones y métodos para tratar sinucleinopatías | |
| US10485844B2 (en) | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor | |
| US10494442B2 (en) | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 | |
| RU2759630C2 (ru) | Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r | |
| JP6554155B2 (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| KR101652530B1 (ko) | 항 cd20 항체 또는 그 cd20-결합 항체 단편을 포함하는 만성 피로 증후군 및 근육통 뇌척수염 치료용 약학 조성물 | |
| AR099084A2 (es) | Composiciones de anticuerpos anti-ctla-4 | |
| EA031489B1 (ru) | Способ лечения ревматоидного артрита | |
| KR20090087908A (ko) | 신생물의 치료를 위한 조성물 및 방법 | |
| CN115427450A (zh) | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 | |
| CL2023000121A1 (es) | Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas | |
| US7914785B2 (en) | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome | |
| JP2025539262A (ja) | 心血管疾患の治療方法 | |
| CL2025001101A1 (es) | Composiciones y métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1. | |
| CL2025000215A1 (es) | Composición farmacéutica de anticuerpo anti-cd20 y uso de la misma | |
| US9486475B2 (en) | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains | |
| AR130041A1 (es) | Formulaciones de anticuerpos anti-tl1a | |
| AR123173A1 (es) | Inmunoconjugados dirigidos a cd46 y métodos de uso de estos | |
| EP2862877A1 (en) | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 | |
| RU2832323C1 (ru) | Способ лечения с использованием антитела против CCL24 | |
| AR130914A1 (es) | Métodos terapéuticos y usos de anticuerpos contra masp-3 humana | |
| AR133828A1 (es) | Anticuerpos anti-tdp-43 y sus usos | |
| KR20260026080A (ko) | 면역 매개 질환의 투여 및 치료와 면역 매개 질환과 관련된 바이오마커 | |
| AR132290A1 (es) | Composiciones farmacéuticas que comprenden anticuerpos que se unen a cd30 y cd3 | |
| AR133637A1 (es) | Formulaciones de alta concentración de anticuerpo anti-receptor de insulina y usos de las mismas |